Detalhe da pesquisa
1.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
J Natl Compr Canc Netw
; 22(3): 175-204, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38626800
2.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
J Natl Compr Canc Netw
; 20(6): 622-634, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714675
3.
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Blood
; 131(15): 1704-1711, 2018 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29305552
4.
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Haematologica
; 104(11): 2258-2264, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923097
5.
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Health Qual Life Outcomes
; 17(1): 173, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31729982
6.
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Lancet Oncol
; 19(9): 1192-1204, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30100375
7.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
N Engl J Med
; 370(11): 997-1007, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24450857
8.
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
Blood
; 125(18): 2779-85, 2015 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25769620
9.
Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
Blood
; 133(9): 990-992, 2019 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30593446
10.
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Br J Haematol
; 185(5): 961-966, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478940
11.
Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
J Cancer Res Clin Oncol
; 149(2): 811-817, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35182224
12.
Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience.
Clin Lymphoma Myeloma Leuk
; 21(12): 861-872, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34389271
13.
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Eur J Cancer
; 148: 411-421, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794441
14.
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Blood Adv
; 5(23): 5098-5106, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34507350
15.
Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.
Clin Lymphoma Myeloma Leuk
; 20(7): 468-479, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32229199
16.
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
Eur J Cancer
; 133: 120-130, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32502876
17.
Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Curr Hematol Malig Rep
; 14(5): 469-476, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31512151
18.
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
J Clin Oncol
; 37(16): 1391-1402, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30995176
19.
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
Clin Cancer Res
; 23(10): 2400-2404, 2017 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27836860
20.
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Lancet Haematol
; 4(1): e24-e34, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27914971